Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex
1 other identifier
observational
52
1 country
1
Brief Summary
This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 26, 2023
CompletedFirst Posted
Study publicly available on registry
March 8, 2023
CompletedStudy Start
First participant enrolled
March 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2024
CompletedApril 14, 2023
April 1, 2023
6 months
February 26, 2023
April 12, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Postoperative residual neuromuscular blockade
TOF ratio \< 0.9
On the arrival of PACU
Interventions
At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
Eligibility Criteria
Patients undergoing elective surgery under general anesthesia will be screened and included in this study.
You may qualify if:
- Patients undergoing elective surgery under general anesthesia.
- American Society of Anesthesiologists grade 1, 2, or 3.
- Aged \>18 years
You may not qualify if:
- Refusal to participate in the study
- Body Mass Index \< 18.5 kg/m2 or \> 35 kg/m2
- History of neuromuscular disease.
- History of allergy to neuromuscular blockade
- Scheduled to transfer to the intensive care unit
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
Related Publications (1)
Koo CH, Lee S, Yim S, Bae YK, Park I, Oh AY. Is quantitative neuromuscular monitoring mandatory after administration of the recommended dose of sugammadex? A prospective observational study. Anaesth Crit Care Pain Med. 2024 Dec;43(6):101445. doi: 10.1016/j.accpm.2024.101445. Epub 2024 Oct 16.
PMID: 39419348DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chang-Hoon Koo
Seoul National University Bundang Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
February 26, 2023
First Posted
March 8, 2023
Study Start
March 15, 2023
Primary Completion
August 31, 2023
Study Completion
August 31, 2024
Last Updated
April 14, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share